Learn more

VIVUS INC

Overview
  • Total Patents
    277
  • GoodIP Patent Rank
    15,213
  • Filing trend
    ⇧ 120.0%
About

VIVUS INC has a total of 277 patent applications. It increased the IP activity by 120.0%. Its first patent ever was published in 1991. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, medical technology and machines are QUADEX PHARMACEUTICALS LLC, NOVADEL PHARMA INC and DEPOMED INC.

Patent filings per year

Chart showing VIVUS INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Najarian Thomas 83
#2 Wilson Leland F 83
#3 Place Virgil A 77
#4 Tam Peter Y 55
#5 Tam Peter 25
#6 Smith William L 23
#7 Gu Leo 20
#8 Banait Narinder S 20
#9 Gesundheit Neil 19
#10 Peterson Craig 18

Latest patents

Publication Filing date Title
US2017319540A1 Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis
AU2016308568A1 Pharmaceutical formulations
AU2016203698A1 Low Dose Topiramate/Phentermine Composition and Methods of Use Thereof
AU2016203699A1 Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity
AU2016262391A1 Compositions and methods for the treatment or prevention of pulmonary hypertension
MX2017009110A Combination therapy for pulmonary hypertension.
CA2958110A1 Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
CA2949094A1 Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use
EP3142644A1 Orally administrable formulations for the controlled release of a pharmacologically active agent
AU2014331995A1 Methods of preventing progression to type 2 diabetes mellitus
AU2014213552A1 Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
AU2014202143A1 Low Dose Topiramate / Phentermine Composition and Methods of Use Thereof
AU2014202124A1 Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity
US2014294950A1 Methods of treating obesity in responder and non-responder populations
US2014288944A1 Methods of regulating access to qsymia to mitigate potential drug-associated risks
AU2013201500A1 Novel combinations comprising a phosphodiesterase-5 inhibitor and their use
AU2012201640A1 Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
US2011224196A1 Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
CA2776971A1 Treatment with cholinergic agonists
US2010087402A1 Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders